Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

USE OF iNOS INHIBITORS TO INCREASE VIRAL YIELD IN CULTURE

a technology of inos inhibitors and culture, which is applied in the direction of viruses/bacteriophages, antibody medical ingredients, dsdna viruses, etc., can solve the problems of limited raav yield, large quantity of clinical grade high-titer raav for gene therapy, and severe restriction of ectromelia replication, etc., to achieve low production of rhsv and hamper efforts

Pending Publication Date: 2022-10-27
GENZYME CORP
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text discusses a new discovery that aurintricarboxylic acid (ATA) can inhibit iNOS and increase the production of herpes simplex virus (HSV). The inventors found that micromolar concentrations of ATA in the presence of fetal bovine serum (FBS) increased the yield of HSV-1 / d27-1 vector and wild-type HSV-1 virus in different cell lines. Other iNOS inhibitors, like dexamethasone and valproic acid, also increased HSV-1 titers. The analysis of HSV-induced iNOS expression showed that it was reduced in HSV+ATA samples. The gene expression analysis also showed that genes involved in inflammatory responses were upregulated, while genes involved in cell cycle and signal transduction were down-regulated. Overall, the patent suggests a potential therapeutic effect of ATA in increasing HSV production.

Problems solved by technology

Despite the above advances, production of large quantities of clinical grade high-titer rAAV virions for gene therapy continues to be challenging due to limitations in scalability of the cotransfection protocol.
Thus, in rHSV-based rAAV manufacturing protocols, the yield of rAAV is limited by the maximal titer of helper rHSV vectors.
This represents a limitation, because yields of d27-1-derived vectors in V27 cells are typically around 1×107 plaque forming units (PFU) / ml.
It has been shown that treatment of macrophages with IFN-γ severely restricts replication of ectromelia virus (EV), vaccinia virus (VV) and HSV-1.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • USE OF iNOS INHIBITORS TO INCREASE VIRAL YIELD IN CULTURE
  • USE OF iNOS INHIBITORS TO INCREASE VIRAL YIELD IN CULTURE
  • USE OF iNOS INHIBITORS TO INCREASE VIRAL YIELD IN CULTURE

Examples

Experimental program
Comparison scheme
Effect test

example 1

Inhibition of HSV-Induced iNOS Levels in V27 Cells using ATA

[0118]V27 cells in Dulbecco's Modified Eagles Medium (DMEM) (Hyclone, Waltham, Mass.) were infected with the HSV-1 d27.1 vector at an MOI of I and treated with 30 μM ATA (Sigma, St. Louis, Mo.), with or without 10% fetal bovine serum (FBS). Control experiments without ATA were also performed. V27 cell lysates were obtained 24 hours post infection (h.p.i.) and Western blots were run on the lysates and iNOS protein was detected by using purified rabbit anti-INOS / NOS Type II pAb (ED Biosciences, Cat #610332). Results are shown in FIG. 1.

[0119]As shown, HSV infection induced INOS expression in those cultures that did not include ATA (lanes 4 and 5). INOS expression was inhibited in the presence of 30 μM ATA (lanes 2 and 3). The presence or absence of 10% FBS did not have an effect on iNOS expression.

example 2

Optimization of ATA-HSV Protocol

[0120]In order to test whether ATA could increase the rHSV-1 d27-1 (d27-1) vector yield in V27 cells, ATA was applied to the media during the infection (Step 1) or dilution steps (Step 2) (FIG. 2A). The d27-1 infection at MOI=0.15 was performed in ⅖ of the final media volume and the remaining ⅗ of the media was added during dilution step.

[0121]ATA treatment delayed HSV-1 plaque formation or cell lysis in V27 cell monolayers. Cytopathic effect (CPE) at the time of harvest, 72 hours post-infection, (hpi) was between 20-60% as compared to 100% CPE in the absence of ATA. Treatment with ATA during the HSV-1 infection step (ATA at Step 1) showed increased d27-1 titers in V27 cells supernatants harvested at 72 hpi (FIG. 4B). The optimal ATA concentration when added during the infection step (ATA 1) was 50 μM and this was further diluted to the final concentration (f.c.) of 20 μM ATA during the dilution step by adding the remaining ⅗ vol of the media. In this...

example 3

Importance of Serum Presence in ATA-HSV Protocol

[0127]Additional experiments were conducted to determine optimal conditions and the effect of the presence or absence of FBS on HSV titer. The serum presence, specifically, 10% fetal bovine serum (FBS), in ATA-containing media was the most important parameter for the ATA-induced HSV-1 titer yield. A supplementation of ATA into serum-free media during the dilution step (ATA at Step 2) caused reduction of virus titer, where the “DRP” titer was reduced below control level and PFU / ml titer was below detection (FIG. 3). An even more dramatic effect in serum-free media was seen when ATA, starting at 3 μM concentration, was supplemented during the infection Step 1 (data not shown) and both DRP / ml and PFU / ml titers were below the detection limit.

[0128]In this experiment, V27 cells were seeded into six well plates the day prior to infection at 6×105 cells / well. HSV 2× infection solution was prepared as follows: HSV-1 d27.1 stock was added to DM...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The use of iNOS inhibitors, including aurintricarboxylic acid, dexamethasone and valproic acid, to increase the yield of a variety of viruses in culture, including recombinant herpesviruses is described.

Description

TECHNICAL FIELD[0001]The present invention relates generally to methods for producing viruses and recombinant virions in culture. In particular, the invention pertains to the use of the iNOS inhibitors, such as aurintricarboxylic acid, dexamethasone and valproic acid to increase the yield of a variety of viruses in culture, including recombinant herpesviruses which can in turn be used as helpers for the production of recombinant adeno-associated virus virions.BACKGROUND[0002]Herpesviruses are highly disseminated in nature and found in most animal species. At least 100 herpesviruses have been characterized, including several from humans, such as herpes simplex virus-1 (HSV-1) and herpes simplex virus-2 (HSV-2), varicella zoster virus (VZV), Epstein-Barr virus (EBV), cytomegalovirus (CMV) and other human herpesviruses such as HHV6 and HHV7. These viruses are responsible for a variety of human diseases, such as skin infections, genital herpes, viral encephalitis, and the like.[0003]HSV...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C12N7/00
CPCC12N7/00C12N2710/16643C12N2710/16651Y02A50/30A61K39/245
Inventor PECHAN, PETERARDINGER, JEFFERYSCARIA, ABRAHAMWADSWORTH, SAMUEL
Owner GENZYME CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com